Scalp, Eyebrow, and Eyelash Hair Regrowth with Continued Ritlecitinib Treatment Among Patients with Alopecia Areata Without Target Efficacy Response at Week 24: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

    Maryanne M. Senna, Seth Forman, Lindsey A. Bordone … Liza Takiya
    Studysummary In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jaad.org →
    Discuss this study in the Community →

    Related research 5

    1. Apremilast Is Efficacious in Refractory Alopecia Areata Journal of dermatological treatment · 2019
    2. Alopecia Areata: A Multifactorial Autoimmune Condition Journal of autoimmunity · 2018
    3. Treating Resistant Cases of Alopecia Universalis Journal of cosmetology & trichology · 2018
    4. Topical Minoxidil for the Treatment of Alopecia Areata PubMed · 2017
    5. Role of the Autoimmune Regulator (AIRE) Gene in Alopecia Areata: Strong Association of a Potentially Functional AIRE Polymorphism With Alopecia Universalis Tissue Antigens · 2002